Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations - Trial NCT06040086
Access comprehensive clinical trial information for NCT06040086 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 1240 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 3
Sep 22, 2023
Dec 07, 2026
Primary Outcome
Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers.
Summary
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab
 administered subcutaneously (SC) in adult participants with symptomatic COPD with a history
 of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment.
 Participants should be receiving optimised treatment with inhaled maintenance therapy
 (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate)
 throughout at least the last 3 months prior to enrolment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06040086
Non-Device Trial